Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00941486 · ClinicalTrials.gov registry record · Phase 2
FST-100 Ophthalmic Suspension in Acute Adenoviral Conjunctivitis
A Phase 2 study, sponsored by Shire.
- Terminated
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00941486 is a Phase 2 study that was terminated before completion, run by Shire. The registered enrollment target is 30 participants.
The verdict
NCT00941486, a Phase 2 study, was terminated before completion, sponsored by Shire.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the efficacy of FST-100 (PVP-I 0.4% and dexamethasone 0.1%) Ophthalmic Suspension in the treatment of suspected acute adenoviral conjunctivitis.
Interventions
- DRUG Placebo
- DRUG FST-100 Ophthalmic Suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2009-06-30 |
| Est. Completion | 2010-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00941486
The ClinicalTrials.gov registry entry for NCT00941486 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00941486 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00941486 about?
NCT00941486 is a clinical study titled "FST-100 Ophthalmic Suspension in Acute Adenoviral Conjunctivitis". The objective of this study is to evaluate the efficacy of FST-100 (PVP-I 0.4% and dexamethasone 0.1%) Ophthalmic Suspension in the treatment of suspected acute adenoviral conjunctivitis.
What is the current status of trial NCT00941486?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2009-06-30. Estimated completion is 2010-06-30.
What interventions are being tested in trial NCT00941486?
The interventions under investigation include: Placebo (DRUG), FST-100 Ophthalmic Suspension (DRUG).
Who is sponsoring clinical trial NCT00941486?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.